How effective are TNF inhibitors in axial spondyloarthritis?
Study of more than 24,000 registry patients shows real-world efficacy and adherence
![Anklyosing spondylitis X-ray of spine](https://www.ausdoc.com.au/wp-content/uploads/2022/08/ankylosing_spondylitis_dreamstime_s_130883125-2.jpg)
About one in three patients with axial spondyloarthritis are likely to achieve inactive disease six months into therapy with a TNF inhibitor, a large registry study suggests.
The real-world analysis of patients naïve to biologics showed that 33% achieved an Ankylosing Spondylitis Disease Activity Score (ASDAS) of below 1.3 at six months.